August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therap..
In recent decades, monoclonal antibody-based cancer treatment has been established as one of the most successful treatment strategies for solid tumors and blood cancers. As the name implies, monoclonal antibodies (mAbs) are antibo..